Older age, scores from nonmotor assessments, reduced dopamine transporter uptake in the caudate, deficit on smell testing, CSF amyloid β (Aβ42) to t-tau ratio, and APOE ε4 status are all known risk factors for cognitive decline in patients with newly diagnosed PD [3]. The gene discussed is MAPT; the disease is Mental deterioration.